GlassScriptPhysician profile
Boyd K Vaziri
NPI 1083685234
$5,562.30
in general payments reported to CMS, 2019-2025
29 companies · $818 in 2025
The $818 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $211 · 2021: $1,345 · 2022: $898 · 2023: $1,092 · 2024: $713 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,623.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,492.70 | 2019-2025 | Tryptyr, Clareon, Precision 1 |
| Medtronic, INC. | $556.45 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $519.92 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Johnson & Johnson Vision Care, INC. | $367.10 | 2022-2024 | Acuvue |
| Nuvasive, INC. | $366.24 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $363.39 | 2019-2021 | |
| Notal Vision, INC. | $235.60 | 2021 | |
| Biotissue Holdings INC. | $219.39 | 2024-2025 | |
| New World Medical,INC. | $208.22 | 2025 | Streamline, Via360, Ahmed Glaucoma Valve |
| Sun Pharmaceutical Industries INC. | $155.73 | 2019-2023 | Cequa |
| Boston Scientific Corporation | $124.96 | 2021 | |
| Amgen INC. | $112.65 | 2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $109.73 | 2019-2022 | |
| Coopervision INC. | $102.68 | 2024 | Myday Contact Lens |
| Abbvie INC. | $99.67 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $92.61 | 2021-2022 | |
| Oyster Point Pharma, INC. | $62.99 | 2022-2024 | Tyrvaya |
| Ocular Therapeutix, INC. | $54.33 | 2021-2023 | Dextenza |
| Glaukos Corporation | $47.94 | 2021 | |
| Allergan, INC. | $40.49 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $38.84 | 2019-2021 | |
| Sight Sciences, INC. | $37.54 | 2023-2025 | Omni Surgical System, Sion Surgical Instrument, Tearcare System |
| Aerie Pharmaceuticals, INC. | $33.62 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $29.95 | 2024 | Xdemvy |
| Dompe US, INC. | $24.06 | 2021 | |
| Rxsight INC | $21.07 | 2025 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Eyevance Pharmaceuticals LLC | $15.77 | 2019 | |
| Rayner Intraocular Lenses Limited | $14.37 | 2024 | Omidria, Rayone Emv, Rayone Aspheric |
| Novartis Pharmaceuticals Corporation | $14.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boyd Vaziri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.